Cargando…

Case Report: Circulating Myeloid-Derived Suppressive-Like Cells and Exhausted Immune Cells in Non-Small Cell Lung Cancer Patients Treated With Three Immune Checkpoint Inhibitors

Immune checkpoint inhibition induced a great step forward in the treatment of non-small cell lung cancer patients. In cancer immune microenvironment many checkpoints were studied and their involvement could represent a mechanism of resistance to cancer immunotherapy. For this reason, the inhibition...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bronte, Giuseppe, Verlicchi, Alberto, De Matteis, Serena, Rossi, Alice, Affatato, Alessandra, Sullo, Francesco Giulio, Gianni, Caterina, Canale, Matteo, Burgio, Marco Angelo, Delmonte, Angelo, Milella, Michele, Crinò, Lucio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8191501/ https://www.ncbi.nlm.nih.gov/pubmed/34122429 http://dx.doi.org/10.3389/fimmu.2021.672219

Ejemplares similares

Advances in Molecular Mechanisms and Immunotherapy Involving the Immune Cell-Promoted Epithelial-to-Mesenchymal Transition in Lung Cancer
por: De Matteis, Serena, et al.
Publicado: (2019)

High Levels of Circulating Monocytic Myeloid-Derived Suppressive-Like Cells Are Associated With the Primary Resistance to Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: An Exploratory Analysis
por: Bronte, Giuseppe, et al.
Publicado: (2022)

Targeting RET-rearranged non-small-cell lung cancer: future prospects
por: Bronte, Giuseppe, et al.
Publicado: (2019)

Circulating Tumour Cells: Detection and Application in Advanced Non-Small Cell Lung Cancer
por: Andrikou, Kalliopi, et al.
Publicado: (2023)

The Clinical Significance of Circulating Tumor DNA for Minimal Residual Disease Identification in Early-Stage Non-Small Cell Lung Cancer
por: Verlicchi, Alberto, et al.
Publicado: (2023)

Concomitant TP53 Mutation Confers Worse Prognosis in EGFR-Mutated Non-Small Cell Lung Cancer Patients Treated with TKIs
por: Canale, Matteo, et al.
Publicado: (2020)

Case Report: Stevens-Johnson Syndrome and Hepatotoxicity Induced by Osimertinib Sequential to Pembrolizumab in a Patient With EGFR-Mutated Lung Adenocarcinoma
por: Gianni, Caterina, et al.
Publicado: (2021)

The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy
por: Canale, Matteo, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors in “Special” NSCLC Populations: A Viable Approach?
por: Bronte, Giuseppe, et al.
Publicado: (2023)

The Interplay Between Programmed Death Ligand 1 and Vimentin in Advanced Non-Small-Cell Lung Cancer
por: Bronte, Giuseppe, et al.
Publicado: (2021)

Liquid Biopsy for EGFR Mutation Analysis in Advanced Non-Small-Cell Lung Cancer Patients: Thoughts Drawn from a Real-Life Experience
por: Ulivi, Paola, et al.
Publicado: (2021)

Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future
por: Nicolini, Fabio, et al.
Publicado: (2020)

Fully Human Antibodies for Malignant Pleural Mesothelioma Targeting
por: Nicolini, Fabio, et al.
Publicado: (2020)

Unveiling mutational dynamics in non‐small cell lung cancer patients by quantitative EGFR profiling in vesicular RNA
por: Pasini, Luigi, et al.
Publicado: (2021)

Immune Checkpoint Molecules and Glucose Metabolism in HIV-Induced T Cell Exhaustion
por: Chan, Yee Teng, et al.
Publicado: (2022)

Gene Mutation Analysis in EGFR Wild Type NSCLC Responsive to Erlotinib: Are There Features to Guide Patient Selection?
por: Ulivi, Paola, et al.
Publicado: (2014)

Wide Next-Generation Sequencing Characterization of Young Adults Non-Small-Cell Lung Cancer Patients
por: Ulivi, Paola, et al.
Publicado: (2022)

The Expression of Programmed Death Ligand 1 and Vimentin in Resected Non-Metastatic Non-Small-Cell Lung Cancer: Interplay and Prognostic Effects
por: Bravaccini, Sara, et al.
Publicado: (2021)

Expression of immune checkpoints and T cell exhaustion markers in early and advanced stages of colorectal cancer
por: Saleh, Reem, et al.
Publicado: (2020)

Insufficiency of compound immune checkpoint blockade to overcome engineered T cell exhaustion in pancreatic cancer
por: Stromnes, Ingunn M, et al.
Publicado: (2022)

Prognosis of ALK-rearranged non-small-cell lung cancer patients carrying TP53 mutations
por: Canale, Matteo, et al.
Publicado: (2022)

Tumor fitness, immune exhaustion and clinical outcomes: impact of immune checkpoint inhibitors
por: Bubie, Adrian, et al.
Publicado: (2020)

Inhibitory immune checkpoints cause exhaustion of viral immunity in coronary artery disease
Publicado: (2022)

PD-1 Immune Checkpoint Blockade and PSGL-1 Inhibition Synergize to Reinvigorate Exhausted T Cells
por: Viramontes, Karla M., et al.
Publicado: (2022)

Hierarchical transcriptional network governing heterogeneous T cell exhaustion and its implications for immune checkpoint blockade
por: Tian, Weihong, et al.
Publicado: (2023)

The prognostic effects of circulating myeloid-derived suppressor cells in non-small cell lung cancer: systematic review and meta-analysis
por: Bronte, Giuseppe, et al.
Publicado: (2022)

Epitherapy and immune checkpoint blockade: using epigenetic reinvigoration of exhausted and dysfunctional T cells to reimburse immunotherapy response
por: McGoverne, Isabella, et al.
Publicado: (2020)

Immune checkpoint receptor VISTA on immune cells is associated with expression of T-cell exhaustion marker TOX and worse prognosis in renal cell carcinoma with venous tumor thrombus
por: Zapała, Łukasz, et al.
Publicado: (2022)

Prognostic Role of Circulating miRNAs in Early-Stage Non-Small Cell Lung Cancer
por: Ulivi, Paola, et al.
Publicado: (2019)

LILRB4, an immune checkpoint on myeloid cells
por: Yang, Ting, et al.
Publicado: (2022)

Tumor-expressed immune checkpoint B7x promotes cancer progression and antigen-specific CD8 T cell exhaustion and suppressive innate immune cells
por: Ohaegbulam, Kim C., et al.
Publicado: (2017)

MYB orchestrates T cell exhaustion and response to checkpoint inhibition
por: Tsui, Carlson, et al.
Publicado: (2022)

How to discriminate non-small cell lung cancer (NSCLC) cases from an Italian administrative database? A retrospective, secondary data use study for evaluating a novel algorithm performance
por: Balzi, William, et al.
Publicado: (2021)

Real-World Outcomes and Treatments Patterns Prior and after the Introduction of First-Line Immunotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer
por: Danesi, Valentina, et al.
Publicado: (2022)

The adaptor protein TRAF3 is an immune checkpoint that inhibits myeloid-derived suppressor cell expansion
por: Zhu, Sining, et al.
Publicado: (2023)

DFNA5 regulates immune cells infiltration and exhaustion
por: Hu, Jian, et al.
Publicado: (2022)

Myeloid Cells as Clinical Biomarkers for Immune Checkpoint Blockade
por: Peranzoni, Elisa, et al.
Publicado: (2020)

T-Cell Exhaustion in Chronic Infections: Reversing the State of Exhaustion and Reinvigorating Optimal Protective Immune Responses
por: Saeidi, Alireza, et al.
Publicado: (2018)

Enforcing the checkpoints: harnessing T-cell exhaustion for therapy of T1D
por: Linsley, Peter S., et al.
Publicado: (2019)

Therapeutic options targeting angiogenesis in nonsmall cell lung cancer
por: Crinò, Lucio, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_2v9fk4okneft0171ja25d4cc4h